Search clinical trials for: Minimal Residual Disease monitoring

Total 381919 results

Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
Personalis Inc.

Recruiting

ctDNA Based MRD Testing for NAC Monitoring in TNBC (B-STRONGER-I)

Minimal Residual Disease | TNBC - Triple-Negative Breast Cancer

United States
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Guangdong Provincial People's Hospital
Haplox

Not yet recruiting

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

Esophageal Squamous Cell Carcinoma | Minimal Residual Disease

China
The First Hospital of Jilin University

Not yet recruiting

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Lung Cancer
University Health Network, Toronto
Princess Margaret Hospital, Canada

Recruiting

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) (NIP IT!)

Melanoma | Breast Cancer | Gastrointestinal Neuroendocrine Tumor

Canada
Tang-Du Hospital

Recruiting

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung | Neoplasm, Residual | Circulating Tumor DNA | Next-Generation Sequencing | Chemotherapy, Adjuvant

China
University Medical Center Ho Chi Minh City (UMC)

Recruiting

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

Gastric Cancer | ctDNA

Vietnam
Sun Yat-sen University

Recruiting

Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia

China
Amgen

Recruiting

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

B-precursor Acute Lymphoblastic Leukemia

United States
Niguarda Hospital

Recruiting

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia (AML FLT3)

Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Italy
University of Rochester

Recruiting

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (MRD)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Invitae Corporation

Active, not recruiting

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment (MARIA)

Cancer | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Mayo Clinic; University of Pennsylvania; University...

Active, not recruiting

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Aggressive | B-cell Non-Hodgkin Lymphoma

United States
Nanfang Hospital of Southern Medical University
Guangxi Medical University; Peking University People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

China
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer | Minimal Residual Disease | Liquid Biopsy | Stage III Colon Cancer
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
University of Surabaya
Department of Anesthesiology and Intensive Therapy, Faculty of Medicine,... and other collaborators

Not yet recruiting

Ability to Maintain Saturation Levels Without Oxygen Supplementation as a Extubation Criteria Without TOF Monitoring Equipment

Anesthesia Intubation Complication
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Gruppo Oncologico del Nord-Ovest

Not yet recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Jinan... and other collaborators

Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Stage II-III Gastric Cancer

China
Fudan University
Shanghai Weihe Medical Laboratory Co., Ltd.

Not yet recruiting

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Pancreatic Ductal Adenocarcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
Zhejiang University

Recruiting

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Acute Lymphoblastic Leukemia

China
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Claus Lindbjerg Andersen
Karolinska Institutet; Medical University of Graz; University of Aarhus; Universitätsklinikum... and other collaborators

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Colorectal Cancer Stage III | Liver Metastasis Colon Cancer

Germany, Denmark, Austria, France, Sweden
FengYan Jin

Not yet recruiting

A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Minimal Residual Disease | AML, Adult
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
University of Aarhus
Aarhus University Hospital

Recruiting

DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies (DANISH_MRD)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage I

Denmark
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Damanhour University

Not yet recruiting

Effect of Eliminating Gastric Residual Volume Monitoring on Ventilator Associated Events

Ventilator Associated Pneumonia
University of Portsmouth
Portsmouth Hospitals NHS Trust

Not yet recruiting

The Effects of Prolonged Head-Down Tilt Lithotomy Position on Lower Limb Haemodynamics (HELP)

Compartment Syndrome Nontraumatic Lower Extremity

United Kingdom
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
WeiWei Xiao
Haplox Biotechnology Co., Ltd.

Recruiting

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Minimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant Chemoradiotherapy

China
University of Southampton
AstraZeneca; Natera, Inc.

Recruiting

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER)

Gastrooesophageal Cancer

United Kingdom
Instituto do Cancer do Estado de São Paulo
Servier

Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil (BRALLA)

Acute Lymphoid Leukemia | Chemotherapeutic Toxicity | Minimal Residual Disease | Gene Abnormality

Brazil
Assistance Publique - Hôpitaux de Paris
CARPEM, Institut du Cancer Paris; Centre de recherche des Cordeliers; METHYS DX

Recruiting

Circulating Tumor DNA Study in Patients With Endometrial Cancer (ctDNA-endo)

Endometrial Cancer

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy

Breast Cancer

Italy
Hebei Medical University Fourth Hospital

Recruiting

Minimally Residual of Esophageal Cancer 001 (ECMRD-001)

Esophageal Carcinoma | Minimal Residual Disease

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
Suzhou Municipal Hospital

Recruiting

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Cervical Cancer

China

Search clinical trials for: Minimal Residual Disease monitoring

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations